spacer
home > ict > Winter 2020
PUBLICATIONS

International Clinical Trials

ict
Winter 2020

   
Text
PDF
bullet
Features
Keeping Trials Connected

Stephen Byrne at KORE

Adopting a more connected clinical trial system can overcome the problems faced by constantly evolving technology and network sunsetting.
 
view
download pdf
bullet
Paediatric Trials
We Can Do Better: Key Considerations for Paediatric Trial Success

Mark Sorrentino at PRA Health Sciences

Enrolment and recruitment challenges in paediatric trials may be mitigated by aspects of trial design that are within our control.
 
 
view
download pdf
RACE for Children Act: Product Development Considerations

Lynne Georgopoulos at Synteract

August 2020 will bring new regulations on cancer drugs for paediatric patients, raising questions on the requirements of drug developers.
 
view
download pdf
Removing Barriers for Paediatric Patients in Clinical Trials

Evelyn Kamau at the MRN

The disparity in clinical trials conducted on adult patients vs children brings important discussions on quality-based care for paediatric patients.
 

 
view
download pdf
Spotlight

Think of the Children: Clinical Trial Considerations at Home

Illingworth Research Group presents how it tackles the challenges of paediatric patient retention and consent in clinical trials.
 

 
view
download pdf
Optimising Trial Design Across the Ages

Michael Oldham, MD, Michelle Petersen, Katharine Shore, and Christina Vonderhaar at Medpace

Regulatory interest in paediatric trials continues to mount, and careful planning across multiple functional areas in trial design is becoming even more vital.
 
view
download pdf
bullet
Clinical Trial Supply
IMP Integrity

Vincent Santa Maria and Tony Heeley at Parexel International

Robust planning and optimisation are essential to future-proof the supply chain for investigational medicinal products.

 
view
download pdf
The Drivers of Success in Ancillary Supply Chain Management

Dr Joanne Santomauro at Ancillare

While pharma companies increasingly focus on outsourcing efforts, effective ancillary supply chain management is often neglected.

 
view
download pdf
Spotlight

The Difference a Step Makes

Signant Health explains the value of a purpose-built supply chain management solution.
 
 
view
download pdf
Comparator Sourcing in Clinical Studies (Part One of Two)

Toby Watkins at CTSS

The first of this two-part article gives a broad overview of the challenges inherent in comparator sourcing, as well as key players in comparator supply.

 
view
download pdf
The Rise of Direct-to-Patient

Brian Swites at Clinigen Group

With a shift in focus in the healthcare industry towards patient centricity, a direct-to-patient supply chain continues to grow in popularity.

 
view
download pdf
Comparator Sourcing in China: Three Key Trends for a New Decade

Viktor Sandstedt at Inceptua

During the 2010s, there were many barriers to trial opportunities in China, but these challenges may be surpassable.

 
view
download pdf
bullet
Data Protection
Harmonising Requirements in the EU

Magdalena Lewandowska at DIA

There are important distinctions to make around the interplay of EU CTR and GDPR across the product lifecycle.

 
view
download pdf
Security, Compliance, and Control

Georgina Stockley at Boldon James

Five key steps can be identified to avoid accidental data loss or leakage, which is vital for maintaining effective data protection.
 

 
view
download pdf
The Impact of GDPR for Health Organisations

Luis Ángel del Valle at SealPath

The 2018 EU GDPR was the first major push by health organisations in a growing effort to protect previously susceptible patient data.
 

 
view
download pdf
   
spacer


Published quarterly in
February, May,
August, and November

News and Press Releases

Bio-Rad Reports Second-Quarter 2021 Financial Results

HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2021. Second-quarter 2021 net sales were $715.9 million, an increase of 33.4 percent compared to $536.9 million reported for the second quarter of 2020.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement